The Searle Company Limited (SEARL) has gained approval from the Drug Regulatory Authority of Pakistan (DRAP) for Denosumab biosimilar injections, marking a significant expansion in its pharmaceutical portfolio. Available in both 60mg and 120mg dosages, the drug will be indicated for osteoporosis management and oncology care respectively.
Read More: Bank of Punjab Delivers 278% Surge in Operating Profit, Announces Historic 10% Interim Cash Dividend
Under a licensing agreement with Mabwell Pharmaceuticals of China, Searle now holds exclusive rights to market and distribute these injections in Pakistan. The positive regulatory outcome represents a pivotal milestone in enhancing Searle’s therapeutic offerings and addressing critical healthcare segments. The company has announced that preparations for the product’s commercial launch are already underway—positioning it to meet both clinical demand and market opportunity.
In addition to diversifying revenue streams, Searle sees the Denosumab launch as a strategic asset in reinforcing its financial performance and delivering sustained shareholder value. The company’s leadership affirmed that this move demonstrates its ongoing commitment to broadening access to advanced treatments for Pakistani patients.
With the introduction of Denosumab, Searle is poised to deliver both therapeutic and economic impact—solidifying its presence in specialty medicine, enhancing earnings quality, and reinforcing its leadership in pharmaceutical innovation.
